Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations

Although the blockade of programmed cell death 1 (PD-1)/PD-ligand (L) 1 has demonstrated promising and durable clinical responses for non-small-cell lung cancers (NSCLCs), NSCLC patients with epidermal growth factor receptor (EGFR) mutations responded poorly to PD-1/PD-L1 inhibitors. Previous studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Miyuki, Watanabe, Satoshi, Tanaka, Hiroshi, Nozaki, Koichiro, Arita, Masashi, Takahashi, Miho, Shoji, Satoshi, Ichikawa, Kosuke, Kondo, Rie, Aoki, Nobumasa, Hayashi, Masachika, Ohshima, Yasuyoshi, Koya, Toshiyuki, Ohashi, Riuko, Ajioka, Yoichi, Kikuchi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461262/
https://www.ncbi.nlm.nih.gov/pubmed/30978241
http://dx.doi.org/10.1371/journal.pone.0215292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461262/
https://www.ncbi.nlm.nih.gov/pubmed/30978241
http://dx.doi.org/10.1371/journal.pone.0215292

Ejemplares similares